ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是找出使用valganciclovir治疗在预防有CMV病风险的HIV感染者的CMV器官损害方面是否安全和有效。符合条件的受试者将是CMV血清阳性，目前未接受CMV预防，没有CMV终末器官疾病的证据，CD4细胞计数为100个/mm3，血浆HIV RNA为400拷贝/毫升。在筛查时，受试者必须要么已经连续接受抗逆转录病毒治疗3个月，要么在进入研究后至少3个月没有接受抗逆转录病毒治疗并且没有计划开始抗逆转录病毒治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to find out whether treatment with valganciclovir is safe and effective in preventing CMV organ damage in persons with HIV infection at risk for CMV disease. Eligible subjects will be CMV seropositive, currently receiving no CMV prophylaxis, with no evidence of CMV end organ disease, have a CD4 cell count <100 cells/ mm3, and a plasma HIV RNA >400 copies/mL. Subjects must either have, at time of screening, been receiving antiretroviral therapy continuously for >3 months or not be receiving antiretroviral therapy and not planning to initiate antiretroviral therapy for at least 3 months after entering the study.